Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management
Kazuki Sawamoto, J. Víctor Álvarez, Matthew Piechnik, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 4, pp. 1517-1517
Open Access | Times Cited: 92

Showing 26-50 of 92 citing articles:

Changes in expression of signal transduction-related genes, and formation of aggregates of GPER1 and OXTR receptors in mucopolysaccharidosis cells
Karolina Pierzynowska, Magdalena Żabińska, Lidia Gaffke, et al.
European Journal of Cell Biology (2022) Vol. 101, Iss. 3, pp. 151232-151232
Closed Access | Times Cited: 10
Models to study basic and applied aspects of lysosomal storage disorders
Ángel Gaudioso, Teresa P. Silva, María Dolores Ledesma
Advanced Drug Delivery Reviews (2022) Vol. 190, pp. 114532-114532
Open Access | Times Cited: 10
Compendium of causative genes and their encoded proteins for common monogenic disorders
Tucker L. Apgar, Charles R. Sanders
Protein Science (2021) Vol. 31, Iss. 1, pp. 75-91
Open Access | Times Cited: 13
Differences in gene expression patterns, revealed by RNA-seq analysis, between various Sanfilippo and Morquio disease subtypes
Karolina Wiśniewska, Lidia Gaffke, Karolina Krzelowska, et al.
Gene (2021) Vol. 812, pp. 146090-146090
Closed Access | Times Cited: 13
Individual Treatment Trials—Do Experts Know and Use This Option to Improve the Treatability of Mucopolysaccharidosis?
Anna‐Maria Wiesinger, Hannah Strobl, Florian B. Lagler
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 416-416
Open Access | Times Cited: 5
Bone Growth Induction in Mucopolysaccharidosis IVA Mouse
Estera Rintz, Angélica María Herreño-Pachón, Betül Çelik, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 9890-9890
Open Access | Times Cited: 5
Iron oxide-coupled CRISPR-nCas9-based genome editing assessment in mucopolysaccharidosis IVA mice
Andrés Felipe Leal, Betül Çelik, Nidhi Fnu, et al.
Molecular Therapy — Methods & Clinical Development (2023) Vol. 31, pp. 101153-101153
Open Access | Times Cited: 5
Characterization of New Proteomic Biomarker Candidates in Mucopolysaccharidosis Type IVA
Víctor J. Álvarez, Susana B. Bravo, María del Pilar Chantada‐Vázquez, et al.
International Journal of Molecular Sciences (2020) Vol. 22, Iss. 1, pp. 226-226
Open Access | Times Cited: 14
Bone-Specific Drug Delivery for Osteoporosis and Rare Skeletal Disorders
Kazuki Sawamoto, J. Víctor Álvarez, Angélica María Herreño, et al.
Current Osteoporosis Reports (2020) Vol. 18, Iss. 5, pp. 515-525
Open Access | Times Cited: 13
The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Different Donors in Recipients With Mucopolysaccharidosis
Yuhua Qu, Hao Liu, Likun Wei, et al.
Frontiers in Pediatrics (2022) Vol. 10
Open Access | Times Cited: 8
The youngest pair of siblings with Mucopolysaccharidosis type IVA to receive enzyme replacement therapy to date: A case report
Marta Frigeni, David Rodriguez‐Buritica, Heather Saavedra, et al.
American Journal of Medical Genetics Part A (2021) Vol. 185, Iss. 11, pp. 3510-3516
Closed Access | Times Cited: 11
Impaired ion homeostasis as a possible associate factor in mucopolysaccharidosis pathogenesis: transcriptomic, cellular and animal studies
Lidia Gaffke, Zuzanna Szczudło, Magdalena Podlacha, et al.
Metabolic Brain Disease (2021) Vol. 37, Iss. 2, pp. 299-310
Open Access | Times Cited: 11
Endoscopic and Image Analysis of the Airway in Patients with Mucopolysaccharidosis Type IVA
Yi-Hao Lee, Chin‐Hui Su, Che-Yi Lin, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 3, pp. 494-494
Open Access | Times Cited: 4
Evidence of epigenetic landscape shifts in mucopolysaccharidosis IIIB and IVA
Viviana Vargas-López, Luisa F. Prada, Carlos Javier Alméciga-Díaz
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Pain management challenges in a patient with mucopolysaccharidosis IVA
Marcus Gurgius, Sarah Donoghue, Robyn A. Wallace
Clinical Case Reports (2024) Vol. 12, Iss. 8
Open Access | Times Cited: 1
Syndromic Retinitis Pigmentosa
Jessica S. Karuntu, Hind Almushattat, Xuan‐Thanh‐An Nguyen, et al.
Progress in Retinal and Eye Research (2024), pp. 101324-101324
Open Access | Times Cited: 1
Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses
Flávia Nathiely Silveira Fachel, Lariane Frâncio, Édina Poletto, et al.
Advanced Drug Delivery Reviews (2022) Vol. 191, pp. 114616-114616
Closed Access | Times Cited: 7
Mucopolysaccharidoses diagnosis in the era of enzyme replacement therapy in Egypt
Ekram Fateen, Zeinab Abdallah, Walaa S. Nazim, et al.
Heliyon (2021) Vol. 7, Iss. 8, pp. e07830-e07830
Open Access | Times Cited: 7
Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes
Juan Politei, Gloria Liliana Porras‐Hurtado, Norberto Guelbert, et al.
JIMD Reports (2021) Vol. 58, Iss. 1, pp. 104-113
Open Access | Times Cited: 7
Activity of daily living in mucopolysaccharidosis IVA patients: Evaluation of therapeutic efficacy
Hui Chen, Shaukat Khan, Betül Çelik, et al.
Molecular Genetics & Genomic Medicine (2021) Vol. 9, Iss. 11
Open Access | Times Cited: 6
Molecular Trojan Horses for treating lysosomal storage diseases
Andrés Felipe Leal, Orhan Kerim İnci, Volkan Seyrantepe, et al.
Molecular Genetics and Metabolism (2023) Vol. 140, Iss. 3, pp. 107648-107648
Closed Access | Times Cited: 2
Gold nanoparticles decorated with monosaccharides and sulfated ligands as potential modulators of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase (GALNS)
Francesca Buco, Camilla Matassini, Costanza Vanni, et al.
Organic & Biomolecular Chemistry (2023) Vol. 21, Iss. 47, pp. 9362-9371
Open Access | Times Cited: 2
Lysosomal storage diseases. Mucopolysaccharidosis types IV, VI, and VII – Morquio, Maroto–Lamy and Sly syndrome
V. N. Gorbunova, Natalia V. Buchinskaia
Pediatrician (St Petersburg) (2022) Vol. 12, Iss. 6, pp. 107-125
Open Access | Times Cited: 4
Splicing Modulation as a Promising Therapeutic Strategy for Lysosomal Storage Disorders: The Mucopolysaccharidoses Example
Juliana Inês Santos, Mariana Gonçalves, Liliana Matos, et al.
Life (2022) Vol. 12, Iss. 5, pp. 608-608
Open Access | Times Cited: 4
The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers
Anna Tylki‐Szymańska, Zsuzsanna Almássy, Violetta Christophidou‐Anastasiadou, et al.
Orphanet Journal of Rare Diseases (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 4

Scroll to top